Drugs / GenSci134
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT07016802 | Jun 2025 → Nov 2026 expected | non-acquired pituitary hormone deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT07450001 | Mar 2026 → Jul 2028 expected | pituitary deficiency | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07450053 | Mar 2026 → Jul 2028 expected | isolated short stature | Changchun GeneScience Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GenSci134 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07450001 ↗ |
| Route | Subcutaneous | “only one dose of GenSci134 to be given, subcutaneous , 6 dose levels will be assigned.” NCT07450001 ↗ |